Skip to main content

Olaratumab Side Effects

Medically reviewed by Last updated on May 10, 2022.

For the Consumer

Applies to olaratumab: intravenous solution

Side effects requiring immediate medical attention

Along with its needed effects, olaratumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking olaratumab:

More common

  • Back pain
  • blurred vision
  • chest tightness
  • chills
  • confusion
  • cough
  • difficulty with breathing
  • difficulty with swallowing
  • dizziness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fast heartbeat
  • feeling of warmth
  • fever
  • headache
  • hives, itching, or skin rash
  • nausea and vomiting
  • no blood pressure or pulse
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • redness of the face, neck, arms, and occasionally, upper chest
  • stopping of heart
  • sweating
  • tightness in the chest
  • unconsciousness
  • unusual tiredness or weakness

Side effects not requiring immediate medical attention

Some side effects of olaratumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Abdominal or stomach pain
  • burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • cracked lips
  • decreased appetite
  • diarrhea
  • difficulty with moving
  • dry eyes
  • fear or nervousness
  • hair loss or thinning of the hair
  • muscle pain or stiffness
  • pain in the joints
  • sensation of pins and needles
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth

For Healthcare Professionals

Applies to olaratumab: intravenous solution


The most common (20% or greater) adverse reactions of this drug plus doxorubicin are nausea, fatigue, musculoskeletal pain, mucositis, alopecia, vomiting, diarrhea, decreased appetite, abdominal pain, neuropathy, and headache.[Ref]


Very common (10% or more): Alopecia (up to 52%)[Ref]


Very common (10% or more): Nausea (up to 73%), mucositis (up to 53%), vomiting (up to 45%), diarrhea (up to 34%), abdominal pain upper/lower (up to 23%)


Very common (10% or more): Lymphopenia (up to 77%), neutropenia (up to 65%), thrombocytopenia (up to 63%), elevated activated partial thromboplastin time (aPTT) (33%)[Ref]


Common (1% to 10%): Treatment emergent immunogenicity[Ref]


Very common (10% or more): Hyperglycemia (up to 52%), appetite decreased (up to 31%), hypokalemia (up to 21%), hypophosphatemia (up to 21%), alkaline phosphatase increased (16%), hypomagnesemia (up to 16%)[Ref]


Very common (10% or more): Musculoskeletal pain (i.e., arthralgia, back pain, bone pain, flank pain, groin pain, musculoskeletal chest pain, myalgia, muscle spasms, neck pain, pain in extremity) (up to 64%)[Ref]

Nervous system

Very common (10% or more): Neuropathy (up to 22%), headache (up to 20%)[Ref]


Very common (10% or more): Dry eyes (up to 11%)[Ref]


Very common (10% or more): Fatigue/asthenia (up to 69%), flushing, fever/chills (up to 14%)[Ref]


Very common (10% or more): Anxiety (up to 11%)[Ref]


Very common (10% or more): Shortness of breath, bronchospasm[Ref]


Frequency not reported: Anaphylactic shock[Ref]


Frequency not reported: Severe hypotension, cardiac arrest[Ref]


1. "Product Information. Lartruvo (olaratumab)." Lilly, Eli and Company (2016):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.